Optimizing Hub Vendor Selection for Specialty Drug Access

The complexity of prior authorization and payer variability often leaves specialty drug programs struggling with execution gaps that digital dashboards cannot resolve. Many brands rely on performance metrics that look impressive in a pitch deck but fail to serve as reliable indicators of real-world patient outcomes. During the live session, the Chief Operating Officer of Elusa Health will address the operational realities of these transitions, specifically examining the risks associated with programs built on incomplete data processed at high speeds.

Attendees will gain a practical framework for evaluating vendor readiness and ensuring continuity when shifting program partners. The discussion will highlight which performance signals are frequently overlooked and how to distinguish between vendors that merely market access performance and those capable of delivering it. The event is scheduled for 10am EDT, offering a deep dive into the strategies required to increase speed to therapy while maintaining stability in a high-stakes clinical environment.